Charles Williamson, MD
Ophthalmology · Baton Rouge, LANPI 1396740122
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (41.0%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 23 manufacturers reported payments, led by AbbVie at 44.0% of the total. 2025 is the largest year on record at $6,511, 5.0 times the $1,303 reported in 2019. Among ophthalmology clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 116 payments — averaging $138.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$7K
- Glaukos Corporation$6K
- Alcon$571
- Bausch & Lomb Americas Inc.$300
- Sun Pharmaceutical Industries Inc.$281
- Johnson & Johnson Surgical Vision, Inc.$204
- plus $2K from 17 others
What the payments were for
- Consulting fees$6,60041%
- Speaking & faculty fees$5,24033%
- Food & beverage$4,13026%
- Entertainment$1381%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 45 | $7,091 |
| Glaukos Corporation | 11 | $6,049 |
| Alcon | 10 | $571 |
| Bausch & Lomb Americas Inc. | 4 | $300 |
| Sun Pharmaceutical Industries Inc. | 4 | $281 |
| Johnson & Johnson Surgical Vision, Inc. | 5 | $204 |
| Staar Surgical Company | 2 | $185 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $164 |
| Microsurgical Technology, Inc. | 1 | $163 |
| Optos, Inc. | 3 | $138 |
| Novartis | 7 | $134 |
| Biotissue Holdings Inc. | 4 | $129 |
| Harrow Eye, LLC | 1 | $124 |
| Mallinckrodt Hospital Products Inc. | 1 | $117 |
| Dompe US, Inc. | 1 | $117 |
| Tearlab Corp | 6 | $83 |
| Lensar, Inc. | 1 | $78 |
| Ivantis, Inc | 1 | $77 |
| NEW World Medical,inc. | 2 | $33 |
| Regeneron Healthcare Solutions, Inc. | 1 | $18 |
| Aerie Pharmaceuticals, Inc. | 1 | $17 |
| Johnson & Johnson Vision Care, Inc. | 1 | $16 |
| Kala Pharmaceuticals, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Travoprost Intraocular Implant - iDose$5,600
- DURYSTA$1,000
- XELPROS$145
- Tecnis IOL$138
- enVista MX60 IOL$128
- XEN$125
- VEVYE$124
- ACTHAR$117
- Oxervate$117
- Wavelight Refractive Suite$111
- WaveLight EX500 Excimer Laser$105
- MIEBO$102
- IOL$102
How this compares
$16,107 in reported general payments places this provider in the 95th percentile of 286 ophthalmology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 31 | $10,518 |
| Restasis MultidoseCyclosporine | 13 | $7,938 |
| CombiganBrimonidine Tartrate/Timolol | 28 | $7,153 |
| Latanoprost | 92 | $1,719 |
| Prednisolone Acetate | 28 | $1,159 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 11 | $613 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 21 | $423 |
| Azelastine Hcl | 13 | $415 |
| Timolol Maleate | 24 | $204 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis Multidose, Combigan | $7,091 | $25,60972 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 286 ophthalmology providers in Louisiana.
Other ophthalmology in Baton Rouge
- Blake WilliamsonBaton Rouge$443K
- David FargasonBaton Rouge$6K
- Philip EhrlichBaton Rouge$6K
- Daniel NelsonBaton Rouge$6K
- Michael MorganBaton Rouge$6K
- Thomas StuckeyBaton Rouge$6K
- George FivgasBaton Rouge$6K
- Devin TranBaton Rouge$5K
- Rebecca MetzingerNew Orleans$63K
- Ze ZhangNew Orleans$44K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.